Research project to analyze factors besides clinical evidence, influencing reimbursement decisions or the hospital benefit catalog 2010-2020, started in Austria

22

Sep 2020

Earlier in September 2020, the Austrian Institute for Health Technology Assessment (AIHTA) published a synopsis of the ongoing research project “Reimbursement decisions for medical procedures in Austria: An analysis of factors – besides clinical evidence – influencing reimbursement decisions for the hospital benefit catalog 2010-2020.”

The project aims to identify specific factors besides clinical evidence that play a pivotal role in the Austrian decision-making process for medical procedures utilizing medical devices, and answer to the following research questions:

  • What role did clinical evidence play in the reimbursement process for individual medical services (Medizinische Einzelleistung; MEL) in Austria over the past ten years?
  • What were other factors taken into account in the reimbursement process to come to a decision that deviates from the evidence-based recommendation?

MEL assessments by the AIHTA and subsequent decisions on the annual maintenance of the Austrian service catalog between 2010 and 2020 are analyzed using a mixed-methods approach.

In the first step, the data from the MEL assessments carried out and the subsequent reimbursement decisions are analyzed using descriptive statistical methods. The existing data set of the AIHTA (data input up to 2016) is completed and represents the data basis for the analysis. Relevant variables include information from HTA reports such as intervention, risk class of the medical device, and quality of the evidence as well as the final reimbursement decisions (mid-September - mid-October 2020).

In the second step, MELs with a decision that deviates from the evidence-based recommendation are identified. This is followed by semi-structured interviews with decision-makers in order to identify further factors that can influence the reimbursement of MELs - without sound scientific clinical evidence (mid-October – mid-November).

The full report in German can be found here

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more